Oncolys BioPharma (TSE:4588) FCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4588 Oncolys BioPharma Inc TSE:4588
40 GF Score
Price 円2,522.00
GF Value 円363.33
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oncolys BioPharma FCF Margin %?

Oncolys BioPharma TSE:4588 -2.06% 40 FCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4588 with a GF Score™ of 40/100 and a GF Value™ of 円363.33 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 950 Biotechnology companies, Oncolys BioPharma ranks worse than 92.11% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Oncolys BioPharma's Free Cash Flow for the three months ended in Dec. 2025 was 円0.00 Mil. Oncolys BioPharma's Revenue for the three months ended in Dec. 2025 was 円0.00 Mil. Therefore, Oncolys BioPharma's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Oncolys BioPharma's current FCF Yield % is -2.63%.

The historical rank and industry rank for Oncolys BioPharma's FCF Margin % or its related term are showing as below:

TSE:4588' s FCF Margin % Range Over the Past 10 Years
Min: -6809.64   Med: -498.87   Max: -18.6
Current: -6144.52

During the past 13 years, the highest FCF Margin % of Oncolys BioPharma was -18.60%. The lowest was -6809.64%. And the median was -498.87%.

TSE:4588's FCF Margin % is ranked worse than
92.11% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs TSE:4588: -6144.52

Oncolys BioPharma FCF Margin % Related Terms

Oncolys BioPharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for Oncolys BioPharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolys BioPharma FCF Margin % Chart

Oncolys BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -271.33 -176.04 -2,129.84 -6,447.89 -6,809.64

Oncolys BioPharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4588 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Oncolys BioPharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolys BioPharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Oncolys BioPharma's FCF Margin % falls into.


TSE:4588
40GF Score
Oncolys BioPharma Inc TSE:4588
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolys BioPharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Oncolys BioPharma's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1943.88/28.546
=-6,809.64 %

Oncolys BioPharma's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Oncolys BioPharma (TSE:4588) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oncolys BioPharma and its competitors. According to the industry distribution chart, Oncolys BioPharma ranks #875 out of 950 companies in the Biotechnology industry, placing it in the top 92.1%.
Is Oncolys BioPharma's FCF Margin % too high?
Oncolys BioPharma's current FCF Margin % is 0.00%. Based on the distribution chart, Oncolys BioPharma ranks #875 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncolys BioPharma ranks #875 out of 950 companies for FCF Margin %. This places Oncolys BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oncolys BioPharma and its competitors. Oncolys BioPharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円363.33, compared to a current price of 円2,522.00 — trading 594.1% above its estimated fair value. The current FCF Margin % is 0.00%. Oncolys BioPharma's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?

Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued. The current stock price of 円2,522.00 is trading 594.1% above its estimated GF Value™ of 円363.33. GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.

Key valuation signals for TSE:4588:

  • FCF Margin %: 0.00%
  • GF Value™: 円363.33 vs. price of 円2,522.00 (594.1% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncolys BioPharma Business Description

Address 4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score

Get the complete analysis for TSE:4588

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,522.00
Price
円363.33
GF Value